[go: up one dir, main page]

AR112227A2 - Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma - Google Patents

Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma

Info

Publication number
AR112227A2
AR112227A2 ARP180101916A AR112227A2 AR 112227 A2 AR112227 A2 AR 112227A2 AR P180101916 A ARP180101916 A AR P180101916A AR 112227 A2 AR112227 A2 AR 112227A2
Authority
AR
Argentina
Prior art keywords
ethyl
trifluoromethyl
cyclohexyl
benzyl
benzyloxy
Prior art date
Application number
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR112227(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR112227A2 publication Critical patent/AR112227A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta solicitud se refiere a una sal de hemi-fumarato del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, a composiciones farmacéuticas que comprenden esta sal, a procesos para formar esta sal, y a su uso en un tratamiento médico. En adición, la presente también se refiere a formas polimórficas de la forma de sal de hemi-fumarato del compuesto [formas A, B, C y D], así como a composiciones farmacéuticas que comprenden estas formas polimórficas, a procesos para obtenerlas, y a su uso en un tratamiento médico. Reivindicación 1: Forma cristalina A del ácido 1-(4-{1-[(E)-4-ciclohexil-3-trifluorometil-benciloxiimino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, ácido (E)-but-2-endioico, caracterizado porque la forma cristalina tiene un patrón de difracción en polvo de rayos X que tiene por los menos un pico específico a aproximadamente 2-q = 20.7º.
ARP180101916 2008-12-18 2018-07-10 Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma AR112227A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
AR112227A2 true AR112227A2 (es) 2019-10-02

Family

ID=42236293

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090104917A AR074694A1 (es) 2008-12-18 2009-12-16 Sal de hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico, y otras formas cristalinas de la misma.
ARP180101916 AR112227A2 (es) 2008-12-18 2018-07-10 Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma
ARP210100712A AR121635A2 (es) 2008-12-18 2021-03-22 Nueva sal y formas cristalinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090104917A AR074694A1 (es) 2008-12-18 2009-12-16 Sal de hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico, y otras formas cristalinas de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210100712A AR121635A2 (es) 2008-12-18 2021-03-22 Nueva sal y formas cristalinas

Country Status (35)

Country Link
US (7) US20120115840A1 (es)
EP (2) EP2379497B1 (es)
JP (1) JP5627597B2 (es)
KR (5) KR101885052B1 (es)
CN (2) CN102256943A (es)
AR (3) AR074694A1 (es)
AU (1) AU2009335924B2 (es)
BR (1) BRPI0923176B8 (es)
CA (2) CA2747437C (es)
CL (1) CL2011001490A1 (es)
CO (1) CO6390104A2 (es)
CY (2) CY1114662T1 (es)
DK (2) DK2676953T3 (es)
EC (1) ECSP11011210A (es)
ES (2) ES2436197T3 (es)
HR (2) HRP20131106T1 (es)
HU (1) HUE034819T2 (es)
IL (3) IL253845B (es)
JO (1) JO2894B1 (es)
LT (1) LT2676953T (es)
MA (1) MA32961B1 (es)
MX (1) MX2011006609A (es)
MY (1) MY152669A (es)
NZ (1) NZ593061A (es)
PE (2) PE20120336A1 (es)
PL (2) PL2676953T3 (es)
PT (2) PT2676953T (es)
RS (2) RS53041B (es)
RU (1) RU2518114C3 (es)
SG (1) SG171785A1 (es)
SI (2) SI2676953T1 (es)
TW (2) TWI591055B (es)
UY (1) UY32330A (es)
WO (1) WO2010080409A1 (es)
ZA (1) ZA201103709B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191842T1 (hr) * 2011-01-07 2019-12-27 Novartis Ag Formulacije imunosupresiva
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
PL3129006T3 (pl) 2014-04-10 2021-07-05 Novartis Ag Formulacja immunosupresanta
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
EP3400211A1 (en) 2016-01-04 2018-11-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2018341136A1 (en) * 2017-09-27 2020-03-12 Novartis Ag Parenteral formulation comprising siponimod
CN111405897A (zh) 2017-09-27 2020-07-10 雷迪博士实验室有限公司 辛波莫德、其盐及其固态形式的制备方法
AU2018343239A1 (en) 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
AU2018341154A1 (en) * 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
US11673860B2 (en) * 2018-01-22 2023-06-13 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
KR20200072795A (ko) 2018-12-13 2020-06-23 고려대학교 산학협력단 옥시이미노메틸벤젠 유도체를 유효성분으로 포함하는 일주기 연관성 질환의 예방 또는 치료용 약학적 조성물
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (en) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Crystalline solid forms of siponimod
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
US12304905B2 (en) 2019-03-28 2025-05-20 1ST Biotherapeutics, Inc. Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof
WO2020234423A1 (en) 2019-05-21 2020-11-26 Synthon B.V. Siponimod maleic acid and fumaric acid salt
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
GB202002560D0 (en) * 2020-02-24 2020-04-08 Johnson Matthey Plc Crystalline forms of voxelotor, and processes for the preparation thereof
US20230212115A1 (en) * 2020-05-29 2023-07-06 Cipla Limited Methods for the preparation of sphingosine 1-phosphate receptor modulators and solid forme thereof
CN116456977A (zh) * 2020-09-25 2023-07-18 斯索恩有限公司 西尼莫德盐和共晶
EP4217341A1 (en) * 2020-09-25 2023-08-02 Synthon B.V. Siponimod salts and cocrystals
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (zh) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 一种羧酸类化合物半富马酸盐的晶型及其制备方法
EP4313941A1 (en) 2021-03-26 2024-02-07 OLON S.p.A. Novel crystalline compound of siponimod hemifumarate
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
DE69203164T2 (de) * 1991-06-04 1995-11-02 Fujisawa Pharmaceutical Co Vorbeugende/therapeutische Zusammensetzung für die Pleuropneumonie des Schweins.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
JP2809510B2 (ja) * 1993-06-08 1998-10-08 久光製薬株式会社 イオントフォレーゼ用システム
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RU2169141C2 (ru) * 1996-04-04 2001-06-20 Санкио Компани Лимитед Производные фенилалкилкарбоновой кислоты и фармацевтическая композиция на их основе
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
ES2245833T5 (es) 1998-12-22 2013-07-19 Genentech, Inc. Antagonistas del factor de crecimiento celular del endotelio vascular y usos de los mismos
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
EP1309556B1 (en) * 2000-12-29 2004-11-24 Pfizer Limited Amlodipine fumarate
JP2005502861A (ja) * 2001-08-10 2005-01-27 サイミックス テクノロジーズ， インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP2000141A1 (en) * 2002-03-20 2008-12-10 Teva Pharmaceutical Industries Ltd. Methods for preparing crystalline quetiapine hemifumarate
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (en) 2003-06-13 2004-12-23 Stephen Dichiera Adjustable bed support and bed
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
KR20130041385A (ko) * 2004-11-29 2013-04-24 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
CN101238099A (zh) * 2005-08-04 2008-08-06 诺瓦提斯公司 维格列汀的盐
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP2010508370A (ja) * 2006-11-07 2010-03-18 ノバルティス アーゲー ヘミフマル酸アリスキレンの結晶形

Also Published As

Publication number Publication date
SG171785A1 (en) 2011-07-28
US20240239743A1 (en) 2024-07-18
DK2379497T3 (da) 2013-11-25
CA2747437C (en) 2018-08-21
CN104803902A (zh) 2015-07-29
KR20110096584A (ko) 2011-08-30
AR074694A1 (es) 2011-02-02
PT2676953T (pt) 2017-06-29
TW201509909A (zh) 2015-03-16
PE20142374A1 (es) 2015-01-30
SI2676953T1 (sl) 2017-07-31
SI2379497T1 (sl) 2013-12-31
HUE034819T2 (en) 2018-02-28
EP2379497A1 (en) 2011-10-26
US20150175536A1 (en) 2015-06-25
JP2012512881A (ja) 2012-06-07
TWI591055B (zh) 2017-07-11
US20140005162A1 (en) 2014-01-02
BRPI0923176B1 (pt) 2020-12-01
PT2379497E (pt) 2013-11-29
AU2009335924B2 (en) 2012-11-08
WO2010080409A1 (en) 2010-07-15
PL2379497T3 (pl) 2014-01-31
HRP20131106T1 (hr) 2013-12-20
ZA201103709B (en) 2012-01-25
CY1114662T1 (el) 2016-10-05
JP5627597B2 (ja) 2014-11-19
CL2011001490A1 (es) 2012-01-13
NZ593061A (en) 2013-08-30
CY1119037T1 (el) 2018-01-10
BRPI0923176A2 (pt) 2016-02-16
US20180118678A1 (en) 2018-05-03
RU2518114C3 (ru) 2021-11-24
MY152669A (en) 2014-10-31
US20120115840A1 (en) 2012-05-10
MX2011006609A (es) 2011-06-30
KR20160129915A (ko) 2016-11-09
IL213071A0 (en) 2011-07-31
CO6390104A2 (es) 2012-02-29
US20210323915A1 (en) 2021-10-21
AU2009335924A1 (en) 2011-06-30
HRP20170916T1 (hr) 2017-09-22
RS56110B1 (sr) 2017-10-31
IL253845B (en) 2022-08-01
US20230357142A9 (en) 2023-11-09
LT2676953T (lt) 2017-06-26
HK1159631A1 (en) 2012-08-03
ES2631203T3 (es) 2017-08-29
AR121635A2 (es) 2022-06-22
MA32961B1 (fr) 2012-01-02
IL253845A0 (en) 2017-09-28
EP2379497B1 (en) 2013-08-21
EP2676953B1 (en) 2017-03-22
US20220402870A1 (en) 2022-12-22
KR20180006492A (ko) 2018-01-17
KR101885052B1 (ko) 2018-08-02
RU2011129222A (ru) 2013-01-27
CA2747437A1 (en) 2010-07-15
ES2436197T3 (es) 2013-12-27
BRPI0923176B8 (pt) 2021-05-25
DK2676953T3 (en) 2017-07-03
PE20120336A1 (es) 2012-04-30
RS53041B (sr) 2014-04-30
JO2894B1 (en) 2015-09-15
KR20160064245A (ko) 2016-06-07
ECSP11011210A (es) 2011-08-31
PL2676953T3 (pl) 2017-09-29
TWI500603B (zh) 2015-09-21
KR20170062554A (ko) 2017-06-07
TW201035048A (en) 2010-10-01
CA2951479A1 (en) 2010-07-15
CN102256943A (zh) 2011-11-23
IL294514A (en) 2022-09-01
EP2676953A1 (en) 2013-12-25
RU2518114C2 (ru) 2014-06-10
UY32330A (es) 2010-07-30
BRPI0923176A8 (pt) 2017-09-12

Similar Documents

Publication Publication Date Title
AR112227A2 (es) Sal de hemifumarato del ácido 1-(4-{1-[(e)-4-ciclohexil-3-trifluorometil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, y otras formas cristalinas de la misma
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
AR053147A1 (es) Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0821362A2 (pt) Composto, uso do mesmo, composição, semente, método para controlar fungos fitopatogênicos, medicamento, e, processos para preparar um antimicótico e para preparar compostos
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
BRPI0804994A2 (pt) forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
CU23515A3 (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
UY30136A1 (es) Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona
CU23615B7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR064809A1 (es) Formas cristalinas
TN2010000539A1 (en) Salts and polymorphs of a tetracylcline compound
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
UA99787C2 (en) Lactams as beta secretase inhibitors
CL2013001221A1 (es) Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto.
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
BRPI0912388A2 (pt) composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
AR082435A1 (es) Valsartan altamente cristalino
BRPI0606199A2 (pt) hidrocloreto de rimonabant, processo para a preparação de um hidrocloreto de rimonabant, composição farmacêutica, forma de dosagem farmacêutica, uso de um hidrocloreto de rimonabant e método de tratamento
BRPI0918664A2 (pt) composição, produto, processo para preparar o composto, e, uso do composto

Legal Events

Date Code Title Description
FB Suspension of granting procedure